Despite the initial promising evidence from small case series of [18F]DCFPyL and 68Ga-PSMA PET imaging in high-grade gliomas and a dosimetry study in the treatment of a GBM patient with [177Lu]Lu-PSMA-617 [20,21,22], a recent study investigated [177Lu]Lu-PSMA therapy in high-grade glioma (HGG) with a focus on intratherapeutic dosimetry and demonstrated that only a minority of HGG patients had significant uptake on [68Ga]Ga-PSMA PET/MRI to be eligible for treatment with [177Lu]Lu-PSMA and among the treated patients, the achieved tumor dose was too low for a sufficient therapeutic effect [23]. This evidence concerns the gene FOLH1 and glioma.